STAT+: The promise of radiopharmaceuticals smacks into safety concerns

In cancer treatment, the pitch has been simple: What if, instead of blasting radiation across patients’ bodies, crop-dusting not only malignant cells but also neighboring healthy tissues, we could shoot chemical weapons directly at only the noxious tumors? That has been the central promise of radiopharmaceuticals, which have grabbed the drug industry’s attention and created a shining new field of drug development. But, as more and more of these therapies move into clinical trials, developers are...